A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Novo Nordisk A/S shares are on track for their worst week this year, after a Super Bowl advertisement touting copycat ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

The Janus Henderson Concentrated Growth Managed Account Portfolio returned 2.44% (gross) and the Russell 1000® Growth Index ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

Shortly after Hims & Hers aired its controversial Super Bowl ad promoting its compounded GLP-1 offerings, Novo Nordisk has ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...